



Treatment with Plasmapheresis, Immunoglobulins and Rituximab for chronic-ac



登录

全部

新闻

图片

购物

地图

更多

设置

工具

找到约 23,300 条结果 (用时 0.51 秒)

Treatment of Antibody-Mediated Renal Allograft Rejection: Improving ...

<https://www.hindawi.com/journals/jjr/2017/6872046/> ▼ 翻译此页

作者 : N Lachmann - 2017 - 被引用次数 : 3 - 相关文章

2017年1月15日 - To date, **plasmapheresis** (PPH) together with the application of intravenous **immunoglobulins** (IVIg) has been the mainstay of ABMR **treatment** [4, 5]. Over the last years monoclonal **antibodies** directed against B cells (**rituximab**) as well as inhibitors of the proteasome (**bortezomib**) have expanded our ...

缺少字词 : active

Chronic Antibody Mediated Rejection of Renal Allograft - Efficacy of ...

<https://www.omicsonline.org/.../chronic-antibody-mediated-rejection-of-rena...> ▼ 翻译此页

Chronic antibody mediated rejection (CAMR) is the main cause for late **kidney transplant** loss, and the **results** of its **treatment** are dissatisfying. ... **Chronic Antibody Mediated Rejection** of Renal Allograft - Efficacy of Combined **Treatment** with Plasma Exchanges, Intravenous **Immunoglobulin** and **Rituximab** (One Center ...

Diagnosis and Management of Antibody-Mediated Rejection: Current ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4285166/> ▼ 翻译此页

作者 : A Djamali - 2014 - 被引用次数 : 150 - 相关文章

2014年1月8日 - It manifests as late **transplant** glomerulopathy (TG) and **results** in a decline in **renal** function. In addition to **pathology mediated** directly by **antibodies**, recent evidence suggests that B cells and plasma cells may themselves influence **rejection** or tolerance. The **clinical** picture of ABMR has become ...

Antibody-Mediated Rejection: A Review - NCBI - NIH

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349636/> - 翻译此页

作者 : JC Garces - 2017 - 被引用次数 : 5 - 相关文章

Chronic antibody-mediated endothelial injury **results** in **transplant** glomerulopathy, manifested as glomerular basement membrane duplication, double contouring, or splitting. **Clinical** manifestations of

Name of Journal: *World Journal of Transplantation*

Manuscript Type: RETROSPECTIVE COHORT STUDY

Treatment with Plasmapheresis, Immunoglobulins and Rituximab for chronic-active antibody-mediated rejection in kidney transplantation: clinical, immunological and pathological results

Mella A *et al.* Treatment with Plasmapheresis, Immunoglobulins and Rituximab for chronic-active antibody-mediated rejection

Alberto Mella, Ester Gallo, Maria Messina, Cristiana Caorsi, Antonio Amoroso, Paolo Gontero, Aldo Verri, Francesca Maletta, Antonella Barreca, Fabrizio Fop, Luigi Biancone

Abstract

AIM

Chronic-active antibody mediated rejection (cAMR) represents one of the major causes of

Match Overview

1 match		
1	Crossref 63 words Messina, Maria, Claudia Ariaudo, Loredana Praticò Barbatto, Silvia Beltramo, Gianna Mazzucco, Antonio Amoroso, An	1%
2	Crossref 61 words Redfield, Robert R., Thomas M. Ellis, Weixiong Zhong, Joseph R. Scalea, Tiffany J. Zens, Didier Mandelbrot, Brenda	1%
3	Crossref 22 words Maria Messina, Claudia Ariaudo, Loredana Praticò Barbatto, Silvia Beltramo et al. "Relationship among C1q-fixing de	<1%

时间不限

2018以来

2017以来

2014以来

自定义范围...

按相关性排序

按日期排序

不限语言

中文网页

简体中文网页

 包括专利 包含引用 创建快讯

小提示：只搜索中文(简体)结果，可在 学术搜索设置 指定搜索语言

[HTML] Comparison of Combination Plasmapheresis/IVIg/Anti-CD20 Versus High-Dose IVIg in the Treatment of Antibody-Mediated Rejection[\[HTML\] wiley.com](#)C Lefaucheur, D Nochy, J Andrade... - ... of *transplantation*, 2009 - Wiley Online Library

... treated by the association PP/IVIg/anti-CD20 compared with those treated by high ... This study compares two successive historic cohorts of AMR treatment, and thus has ... data presented here regarding the use of combination plasmapheresis/IVIg/rituximab therapy are encouraging ...

☆ 99 被引用次数：250 相关文章 所有 10 个版本

[HTML] Antibody-mediated microcirculation injury is the major cause of late kidney transplant failure[\[HTML\] wiley.com](#)G Einecke, B Sis, J Reeve, M Mengel... - ... of *Transplantation*, 2009 - Wiley Online Library

... antisera (30 min, Cy2-conjugated affinity purified goat anti-mouse IgG, Jackson ImmunoResearch ... biopsied late: diseases operating in grafts biopsied early are more amenable to treatment ... C4d staining was diffusely positive in 24 biopsies, mostly late chronic-active ABMR (21 ...

☆ 99 被引用次数：515 相关文章 所有 11 个版本

[HTML] Outcome of Subclinical Antibody-Mediated Rejection in Kidney Transplant Recipients with Preformed Donor-Specific Antibodies[\[HTML\] wiley.com](#)A Loupy, C Suberbielle-Boissel, GS Hill... - ... of *Transplantation*, 2009 - Wiley Online Library... From 2006 onward, the final 18 patients in group A received additional prophylactic anti-CD20 therapy (Rituximab Roche pharmaceuticals), at a dose of 375 mg/m² at ... Treatment of acute rejection episodes. Acute cellular rejection episodes were treated with high-dose steroids ...

☆ 99 被引用次数：269 相关文章 所有 7 个版本

[HTML] The Spectrum of Antibody-Mediated Renal Allograft Injury: Implications for Treatment[\[HTML\] wiley.com](#)J Gloor, F Cosio, DJ Lamer... - ... of *Transplantation*, 2008 - Wiley Online Library

... able in treating acute AMR, and reports of their ...



找到约 15,100 条结果 (用时 0.42 秒)

Antibody-Mediated Rejection in Kidney Transplantation: A Review

<https://www.hindawi.com/journals/jtrans/2012/193724/>  翻译此页

作者: C Puttarajappa - 2012 - 被引用次数: 105 - 相关文章

2012年1月9日 - **Antibody mediated rejection** (AMR) poses a significant and ... of the antibody mediated processes in **kidney transplantation**. ... the various histopathological and **clinical** manifestations of AMRs, Intravenous **Immunoglobulin** (IVIG) **Rituximab results** in prolonged and profound B-cell depletion which may ...

缺少字词: active

Antibody-Mediated Rejection: A Review - NCBI - NIH

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5349636/> - 翻译此页

作者: JC Garces - 2017 - 被引用次数: 5 - 相关文章

Chronic antibody-mediated endothelial injury **results** in transplant ... Current strategies for the **treatment** of AMR include **antibody** depletion with **plasmapheresis** (PLEX), ... of the current **immunologic** barriers that prevent or delay **kidney transplantation**. **Plasmapheresis**, Intravenous **Immunoglobulin**, and **Rituximab**.

Rituximab and Monitoring Strategies for Late Antibody-Mediated ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5828696/> - 翻译此页

作者: S Parajuli - 2017 - 相关文章

2017年10月27日 - **Results**. Patients had biopsy 7.3 ± 7 years after **transplant** and were followed for 15.9 ... **Antibody-mediated rejection** (ABMR) is an important barrier for ... of patients with **chronic active** ABMR, 75% of patients lost their **kidney** ... In this study, **treatment** with steroids and intravenous **immunoglobulin** (IVIG) was ...

Treatment of Chronic Active Antibody Mediated Rejection After Kidney ...

<https://clinicaltrials.gov/ct2/show/NCT03436134>  翻译此页

2018年2月16日 - A **chronic** ABMR is the **result** of the appearance de novo production of ... B lymphocytes/plasma cells of the patient (with **rituximab** for example). ... **Kidney Transplantation** **Antibody Mediated Rejection**, Other: ... of **Plasma exchange** as **treatment** of **chronic antibody mediated rejection**. **Immunologic** Factors

IVIG and rituximab for treatment of chronic antibody-mediated rejection ...

onlinelibrary.wiley.com/doi/10.1111/j.1432-2277.2012.01544.x/full  翻译此页

2012年8月16日 - **Chronic antibody-mediated rejection** (AMR) is the major cause of late renal ... We